Monte Rosa Therapeutics (GLUE) Return on Invested Capital (2023 - 2025)
Historic Return on Invested Capital for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to 0.03%.
- Monte Rosa Therapeutics' Return on Invested Capital rose 6300.0% to 0.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.03%, marking a year-over-year increase of 6300.0%. This contributed to the annual value of 0.42% for FY2024, which is N/A changed from last year.
- Per Monte Rosa Therapeutics' latest filing, its Return on Invested Capital stood at 0.03% for Q3 2025, which was up 6300.0% from 0.05% recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Return on Invested Capital ranged from a high of 0.05% in Q2 2025 and a low of 0.87% during Q1 2024
- Over the past 3 years, Monte Rosa Therapeutics' median Return on Invested Capital value was 0.5% (recorded in 2024), while the average stood at 0.42%.
- In the last 5 years, Monte Rosa Therapeutics' Return on Invested Capital skyrocketed by 4000bps in 2024 and then soared by 8700bps in 2025.
- Quarter analysis of 3 years shows Monte Rosa Therapeutics' Return on Invested Capital stood at 0.79% in 2023, then soared by 50bps to 0.39% in 2024, then surged by 108bps to 0.03% in 2025.
- Its Return on Invested Capital stands at 0.03% for Q3 2025, versus 0.05% for Q2 2025 and 0.01% for Q1 2025.